Compass Therapeutics (CMPX) Enterprise Value (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Enterprise Value for 3 consecutive years, with -$209.5 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 65.3% to -$209.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$209.5 million through Dec 2025, down 65.3% year-over-year, with the annual reading at -$209.5 million for FY2025, 65.3% down from the prior year.
- Enterprise Value hit -$209.5 million in Q4 2025 for Compass Therapeutics, up from -$220.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$100.9 million in Q2 2025 to a low of -$220.5 million in Q3 2025.
- Historically, Enterprise Value has averaged -$155.8 million across 3 years, with a median of -$154.5 million in 2023.
- Biggest YoY gain for Enterprise Value was 30.96% in 2025; the steepest drop was 65.3% in 2025.
- Year by year, Enterprise Value stood at -$152.5 million in 2023, then increased by 16.88% to -$126.7 million in 2024, then tumbled by 65.3% to -$209.5 million in 2025.
- Business Quant data shows Enterprise Value for CMPX at -$209.5 million in Q4 2025, -$220.5 million in Q3 2025, and -$100.9 million in Q2 2025.